Search research articles
Contact Us
Filters
Showing results (1-10 of 28) with videos related to
Page
of 3
Sort By:
Journal of Biopharmaceutical Statistics
|
June 7, 2014
Performance of adaptive designs for single-armed phase II oncology trials
Meinhard Kieser, Stefan Englert
Biometrical Journal. Biometrische Zeitschrift
|
July 23, 2013
Optimal adaptive two-stage designs for phase II cancer clinical trials
Stefan Englert, Meinhard Kieser
Biometrics
|
December 14, 2011
Improving the flexibility and efficiency of phase II designs for oncology trials
Stefan Englert, Meinhard Kieser
Pharmaceutical Statistics
|
March 14, 2012
Adaptive designs for single-arm phase II trials in oncology
Stefan Englert, Meinhard Kieser
Statistics in Medicine
|
March 18, 2015
Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials
Stefan Englert, Meinhard Kieser
BMC Medicine
|
July 27, 2023
Why estimands are needed to define treatment effects in clinical trials
Oliver N Keene, Helle Lynggaard, Stefan Englert, et al.
Pharmaceutical Statistics
|
March 29, 2024
Time-to-event estimands and loss to follow-up in oncology in light of the estimands guidance
Jonathan M Siegel, Hans-Jochen Weber, Stefan Englert, et al.
Journal of Alzheimer'S Disease : JAD
|
October 5, 2020
Mismatch of Subjective and Objective Risk of Falling in Patients with Dementia
Klaus Hauer, Michael Schwenk, Stefan Englert, et al.
Gerontology
|
August 30, 2014
Sensor-derived physical activity parameters can predict future falls in people with dementia
Michael Schwenk, Klaus Hauer, Tania Zieschang, et al.
BMC Geriatrics
|
June 14, 2014
Improvements in gait characteristics after intensive resistance and functional training in people with dementia: a randomised controlled trial
Michael Schwenk, Tania Zieschang, Stefan Englert, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 28) with videos related to
Sort By:
Page
of 3
Journal of Biopharmaceutical Statistics
|
June 7, 2014
Performance of adaptive designs for single-armed phase II oncology trials
Meinhard Kieser, Stefan Englert
Biometrical Journal. Biometrische Zeitschrift
|
July 23, 2013
Optimal adaptive two-stage designs for phase II cancer clinical trials
Stefan Englert, Meinhard Kieser
Biometrics
|
December 14, 2011
Improving the flexibility and efficiency of phase II designs for oncology trials
Stefan Englert, Meinhard Kieser
Pharmaceutical Statistics
|
March 14, 2012
Adaptive designs for single-arm phase II trials in oncology
Stefan Englert, Meinhard Kieser
Statistics in Medicine
|
March 18, 2015
Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials
Stefan Englert, Meinhard Kieser
BMC Medicine
|
July 27, 2023
Why estimands are needed to define treatment effects in clinical trials
Oliver N Keene, Helle Lynggaard, Stefan Englert, et al.
Pharmaceutical Statistics
|
March 29, 2024
Time-to-event estimands and loss to follow-up in oncology in light of the estimands guidance
Jonathan M Siegel, Hans-Jochen Weber, Stefan Englert, et al.
Journal of Alzheimer'S Disease : JAD
|
October 5, 2020
Mismatch of Subjective and Objective Risk of Falling in Patients with Dementia
Klaus Hauer, Michael Schwenk, Stefan Englert, et al.
Gerontology
|
August 30, 2014
Sensor-derived physical activity parameters can predict future falls in people with dementia
Michael Schwenk, Klaus Hauer, Tania Zieschang, et al.
BMC Geriatrics
|
June 14, 2014
Improvements in gait characteristics after intensive resistance and functional training in people with dementia: a randomised controlled trial
Michael Schwenk, Tania Zieschang, Stefan Englert, et al.
Page
of 3